1. Can you give us an overview of the drug development services the company provides to the pharmaceutical industry?
At Pfizer CentreOne we aspire to be the CDMO partner of choice. Over the last several years our team has been working to expand our development services offerings so we can truly be an end-to-end CDMO, from development through to commercial manufacture.
We are fortunate to have access to Pfizer’s network of resources and expertise that allows us to deliver first-class medicines to the patients who need them. Our core offerings in development services for biopharmaceutical products include:
- Formulation
- Manufacturing
- Analytical testing
- Validation
- Method development
- Clinical manufacturing
Regulatory strategies also play a significant role in the drug development program and our Pfizer CentreOne professionals have decades of experience facilitating early engagement with regulators and offering customized submission support for countries around the world.
2. What are some general drug development industry issues pharmaceutical companies are facing?
We are seeing an influx of innovative molecules entering the market for specific targeted therapeutic areas where absorption and bioavailability pose challenges.
Today 90% of molecules in the discovery pipeline are poorly water soluble, increasing the risk of low bioavailability resulting in suboptimal drug delivery, ineffective drug efficacy, and side effects.
The bioavailability challenge of these new molecules poses a real threat to drug development timelines and ultimately getting life-saving medicines into the hands of patients as quickly as possible.
3. Specifically, why should potential clients look to Pfizer CentreOne for drug development services? What technologies and expertise set you apart from companies offering similar services?
Our development expertise come from years of experience solving challenges for both Pfizer and our customers’ products. Our experts collaborate with customers to optimize formulations and processes, working to reduce downstream risk wherever possible. We have access to several innovative technologies for drug development, including osmotic pump technologies and low dose active coating for oral solids development with process analytical technology capabilities enabling solutions for bioavailability challenges.
We are backed by the scientific power of Pfizer, which includes its experience in completing development and tech transfers to bring Pfizer products to market. We are just as committed to the success of our customers' development and tech transfers as such success aligns with Pfizer's purpose of creating breakthroughs that change patients' lives.
We also have a long-standing commitment to protecting the environment and the communities in which we operate, including a commitment to all 17 of the U.N. Sustainable Development Goals. We continue to find ways to minimize our impact on the environment during the manufacturing of pharmaceuticals. In 2020, Pfizer Inc. recorded a 33 percent reduction in direct Greenhouse Gas Emissions.
At our Kalamazoo manufacturing site in Michigan, USA, we’ve implemented projects that have annually reduced greenhouse gas emissions by 24,000 metric tons and hazardous waste disposal volume by 10 million kilograms.
4. Please describe your project approach. How do ensure small companies get the same level of project management and expertise that large companies get?
We are always focused on achieving the best results for patients, and our goal is to provide all our customers with an experience rooted in transparency, timely communication, and reliability. We collaborate with our customers, asking questions and challenging the norm to find and create customized solutions together.
In addition, our partners gain access to a robust project team to enlist the right experts from Pfizer’s enterprise-wide talent pool at the right time during a product’s progression. Customers benefit from a single point of contact who will ensure cross-functional support from start to finish, supported by a dedicated team of experts. A key element to our approach is establishing a joint governance process; as an innovative pharmaceutical company, we know how to bring a product to market and all the complexities that accompany the process.
For every project we touch, our project management system provides comprehensive prioritization, tracking, notification of milestones, and our colleagues are trained in best practices to ensure our customer's confidential information is safeguarded.
5. Looking ahead how will Pfizer Centre One continue to provide industry leading drug development services to its current and future clients?
We continuously invest in our people, processes, and technology including our development and manufacturing resources and capabilities. We employ some of the finest talent in the industry, invest heavily in their training and development, and then support them in all aspects of their career. We have also invested morethan $1B into our manufacturing sites annually.
With access to Pfizer's enterprise-wide resources, our experts are able to leverage the broader organization's investments to drive our customers’ projects forward.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!